–
The Cancer Immunology Unit -UNICA- of the Research Institute of the Hospital 12 de Octubre i + 12, led by Dr. Luis Álvarez-Vallina, has coordinated the design of an antibody capable of promoting the response of the immune system against cells tumors and eliminate
adverse reactions associated with conventional treatments. It is a novel strategy within precision and personalized medicine that will improve current immunotherapy and promote the effectiveness of treatment in the patient.
The prestigious journal Clinical Cancer Research has recently published the study, An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity, which shows that the new antibody has a very antitumor activity. significant and no toxicity or side effects in colorectal cancer, triple negative breast cancer, and non-small cell lung cancer.
Unlike current antibodies, these new molecules called trimerbodies are capable of identifying a tumor and inhibiting its growth in a more efficient and less toxic way. The new antibody is also characterized by being “humanized”, that is, it would be able to be used in clinical trials in cancer patients without generating adverse effects, according to the conclusions of the study, in which researchers from the services of Medical Oncology and Pathological Anatomy of October 12.
The tests carried out in the laboratory and later in mouse models, using
injection of humanized antibodies and tumor cells have shown that
the clinical application of this type of immunotherapy in cancer patients could
generate a much higher and safer effectiveness than that obtained by the treatments
currently approved.
The project, coordinated by the Hospital 12 de Octubre, is the result of an international multicenter collaboration in which different cancer research groups from the Puerta de Hierro-Majadahonda Hospital, the Applied Medical Research Center -CIMA- of the University of Navarra, the National Center for Oncological Research –CNIO-, the Center for Energy, Environmental and Technological Research –CIEMAT-, the Higher Council for Scientific Research –CSIC-, the Cooperative Research Center in Biosciences of Vizcaya –CIC bioGUNE-, the Aarhus University of Denmark and the biotech company
Spanish Leadartis SL
–
